CENTOGENE Announces Global Expansion of COVID-19 Testing
|
DGAP-News: CENTOGENE AG
/ Key word(s): Miscellaneous
CENTOGENE Announces Global Expansion of COVID-19 Testing Cambridge, MA, USA & Rostock/Berlin, Germany, May 05, 2020 ─ CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced it will expand its testing efforts for the novel coronavirus, or COVID-19. The Company was previously testing in Germany's Mecklenburg-Western Pomerania region, and will now be offering its extensively validated SARS-CoV-2 RT-PCR testing to the rest of the world. This announcement comes as one of the Company's latest initiatives to support the earliest possible diagnosis of COVID-19 and prevent a further outbreak. CENTOGENE Senior Vice President of Clinical Lab Operations and Head of the Hamburg Laboratory Dr. Florian Vogel stated, "With the recent addition of our new lab and streamlined COVID-19 testing workflows via high-throughput, high-quality analyses, we have been able to significantly increase our testing capacities ─ enabling us to provide time-sensitive diagnostic solutions to patients and physicians around the world." Prof. Arndt Rolfs, CEO of CENTOGENE, said, "To overcome this global crisis, we must significantly increase testing efforts around the world to support early diagnosis and minimize the outbreak of COVID-19. Leveraging our existing infrastructure and capabilities, we have developed a fully validated sample collection kit to detect SARS-CoV-2 RNA. Additionally, we have opened an entirely new lab in Hamburg. The entire workflow, starting with sampling and ending with sending results to tested individuals, requires a strong combination of lab technology and IT support, e.g., secured patient data using blockchain technology. With tests being performed in ISO 15189 accredited medical diagnostic laboratories, and patient data privacy ensured by using state-of-the-art security mechanisms, CENTOGENE offers complete assurance and peace of mind as a partner of choice. We are convinced that with these latest achievements in our series of efforts in the fight against COVID-19, we will be able to support a return to new normalcy." ### About CENTOGENE CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.5 billion weighted data points from approximately 500,000 patients representing over 120 different countries as of December 31, 2019. The Company's platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients' blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners' ability to bring orphan drugs to the market. As of December 31, 2019, the Company collaborated with over 39 pharmaceutical partners covering over 45 different rare diseases.
Media Contact: CENTOGENE MC Services AG Important Notice and Disclaimer This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project" or "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please refer to the Risk Factors section in our registration statement on form F-1, as amended (file no. 333-234177) and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
05.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Editor Details
-
Company:
- EQS Newsfeed
- Website:
